Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope you're right, just took a gamble with a .0113 purchase today!
Yeah I hate that too. Timothy Skykes and creeps like him have killed the OTC even before Biden!!!
BTW, That was me slapping the ASK at .0113 for 321,000+ shares at .0113 for a starter
Good day 2 buy - congrats
Yeah, this is one of those kind of stocks where you see it go up 41% on 10 million volume and then super low volume next day and then in 1 or 2 days BOOM 10 million sets it off again!.
Super Low Floater just over 20 million shares in the Float!
I would not be surprised we so 10 or more volume tomorrow setting this off. Low volume take down day; not concerned at all
$FSRD Don't miss the next move in a few hours; 18 hours and 15 minutes from now to be exact!
I assume it is you that gave me a follow today and I gave you a follow in return!
Well for Tuesday I'm in FSR............d @ an average price of .65 and for whatever weird reason BOXD took a chit when they had so much going for them but in this scarce opportunity Biden Admin Market, I think BOXD will make bank soon and I hope to get back in them very soon!
It's understandable the buzz you're hearing because there are not many stocks that hit scanners this weekend the way this one has I'm going for higher than $3 because I think it can do it. This IPO is a real company making money!!
Got a swing trade in AH session to lower my average down to .65
Looking forward to fantastic Tuesday with FSRD!
I should have slapped the ASK at .71 paid .74 instead; Looks like Fast Radius is about to make a Fast and Furious movement!
I thought so too.
Yeah that was HUGE NEWS this morning; should be a fun week w/ this one!
Well, when it wasn't trading right this morning I got out put it into another stock & sure I'll get back in again soon
What does CTB mean? I tried to search engine it with Fintel but got nothing.
Why would anyone want to short BOXD from these levels? Not only is it crazy since the stock can easily go up and anyone shorting would lose a lot and there is so much more to be gained going long from this price level?!?!
60 million volume 1st 3 1/2 hours of the trade session and 4.6 million in the past 1 1/2 hour - when we hit a certain number this will pop! Still another 1.5 hrs to go
What did you pay for the puts and what day??
This comment had me a little worried when I read it yesterday because I sold Friday after hours @ $2.56 and put in GTC Extended Hours to repurchase @ $2.30 that did not get filled on Friday after selling but luckily got it repurchased @ $2.30 pre-market today! If it had opened up @ $4 today I would have shit myself and got drunk all week!
Opportunities like BOXD are a bit more scarce these days!
It will probably keep dropping, I'm out. Consolidation. I think that's the new word for RS 1 for 20!
Once AKAN goes next week it's going to go big time imo. Anybody claiming different is shall we say, a fraud!
I ask for an example but instead you prove my point - IPO hits the market on the first day it's released by the underwriter and immediately has a drastic drop as they all do! And then they find their bottom and go up from there!
This is why it is stupid to bash this stock Good luck finding another stock coming of an established bottom on the Big Boards or even the OTC like this with this TINY FLOAT: find it for me - it does not exist!
TORONTO, May 20, May 20, 2022 (GLOBE NEWSWIRE via COMTEX) -- Highlights:
In 2021, the Company generated gross revenue of approximately $14.9 million and generated gross revenue of $4.3 million during the fourth quarter.
During the year, the Company sold 6,627,052 grams of dried cannabis flower, an increase of 372% as compared to the prior year.
The Company has expanded in format sizes beyond is signature 3.5 gram jars to include 7 gram and 14 gram bags.
Flowr launched BC Dog Walkers in Ontario, British Columbia, and Alberta. The BC Dog Walkers highlight the Company's ability to react to consumer demand and bring novel formats to market.
Flowr exported its first shipment of medical cannabis from Kelowna, British Columbia to Israel in December 2021 valued at $825,000, which has opened up an import revenue channel for the Company.
In 2021, the Company repaid approximately $15.6 million in overall indebtedness and had $5.7 million of principal outstanding pursuant to its senior secured facility with ATB Financial at the end of the year. The Company expects to fully repay its senior credit facility with the proceeds of certain non-core asset sales.
Key Subsequent Events:
KRS Sale - Company entered into an agreement to sell its interest in the KRS R&D facility to Hawthorne for an aggregate purchase price of $16 million.
Holigen Sale - During the second quarter of 2022, Flowr completed the sale of Holigen Limited for aggregate consideration of over $35 million. The consideration was comprised of: (i) approximately $3,750,000 in cash; (ii) 1,900,000 common shares in the capital of Akanda Corp.; (iii) the indirect assumption by Akanda of indebtedness of approximately $5,100,000; and (iv) $1,234,000 of interim funding to Holigen.
New Genetics - Flowr has introduced several high-THC strains, including BC Clementine Crush, BC Lemon Ice, BC Spiced Grape and BC Mango Melon OG.
Non-Core Asset Sales - The Company is in the process of monetizing other non-core assets, which it expects to result in approximately $3 million to $4 million in cash proceeds.
TORONTO, May 20, 2022 (GLOBE NEWSWIRE) -- The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) ("Flowr" or the "Company") herein announces its financial and operational results for the fourth quarter and fiscal year ended December 31, 2021. All financial information in this news release is reported in thousands ('$000s) of Canadian dollars and represents results from continuing operations, unless otherwise indicated.
Tom Flow, Interim Chief Executive Officer of Flowr commented:
"2021 was a pivotal year for Flowr as we renewed our focus on maintaining our status as a premium cannabis producer and making the necessary changes to our business operations to reach profitability. The Company made significant progress towards this objective, as we continue to take the necessary steps to reduce costs and drive revenues. In Q4 2021, we achieved new records in gross and net revenue at $4.4 million and $3.9 million, respectively, contributed by our previously announced strategy of introducing exciting new genetics and formats, enhancing our retail penetration, and solidifying our world class operations out of the K1 facility.
Operationally, the K1 facility has been now fully operational since the second half of 2021 and each grow room is being utilized to ensure our fixed costs are being spread out over a higher number of production grams. We have increased our product offerings significantly with the launch and success of Strawnana, Sour Sis, BC Dog Walkers, and in 2022 introduced several new exciting strains including BC Clementine Crush, BC Lemon Ice, BC Spiced Grape and BC Mango Melon OG, with more planned for the rest of 2022. We have also seen significant growth in retail penetration across our core markets with store distribution well over 50%.
Financially, we have strived to improve our financial position by reducing costs, shedding non-core assets and licenses, significantly reducing overall indebtedness, and raising additional equity capital. The sale of the KRS R&D facility and Holigen as previously announced will further reduce the Company's indebtedness to approximately $10 million, including $5.7 million under the senior credit facility and $5 million of convertible debentures, with further paydowns to the senior credit facility expected in the second quarter. The Company has reduced SG&A expenses each quarter since the end of 2020 with Q4 2021 SG&A 16% lower than the same period in 2020.
As previously announced, we have closed the sale of Holigen for what we believe to be favourable terms for Flowr shareholders. The Company undertook a robust sale process and was able to transact upon a deal that gave Flowr a significant amount of cash on closing to solidify its balance sheet and also preserve the upside related to our European operations. We still believe the European market is on the cusp of regulatory change and we believe that Holigen will be able to take advantage of those opportunities with the capital and excellent management team from Akanda.
Consolidated gross revenue for Q4 2021 amounted to $4,292, representing a 108% increase compared with $2,066 in Q4 2020. Consolidated net revenue during Q4 2021 was $3,801, 138% higher than the $1,600 earned in Q4 2020. Both gross revenue and net revenue for Q4 2021 were the highest quarterly revenue recorded by the Company since inception, contributed by increases in cannabis sales in Flowr Canada.
Net revenue from Flowr Canada during Q4 2021 amounted to $3,679 compared with $1,533 in the same period of 2020, while revenue earned by Holigen was $122 during Q4 2021 compared with $67 in the same period 2020. Net revenue from Flowr Canada in Q4 2021 was a new record and the third straight quarter of revenue growth, being 61%, 88%, and 4% higher than the net revenue for Q3, Q2, and Q1 2021 respectively. The increase in revenue from Flowr Canada was contributed by higher grams of products sold during Q4 2021 and the introduction of the new strain BC Strawnana and a new format of pre-rolls, partially offset by a decrease in average prices.
Full year gross revenue for 2021 amounted to $14,957 compared with $9,441 in 2020, representing a 58% increase. Net revenue for the full year 2021 totaled $12,348 compared with $7,513 in 2020, representing a 64% increase.
Net revenue from Holigen related to tolling service revenue earned in Portugal, which amounted to $122 during Q4 2021 and $712 for the full year 2021, compared with $67 for the same respective periods in 2020.
SG&A expenses for Q4 2021 further declined to $3,900 compared with $4,614 in Q4 2020, representing a 15% reduction. SG&A expenses for the full year 2021 was $16,327, 12% lower than the $18,613 recorded for the full year 2020. Since the end of 2020, Flowr has significantly reduced SG&A expenses each quarter, reflecting the cost reduction measures the Company implemented during 2021.
Cost of sales for Q4 2021 was $5,262 compared with $2,904 for Q4 2020. The increase in cost of sales resulted from a significantly higher volume of cannabis sold during the current quarter at 1,407 kilograms compared with 311 kilograms sold during Q4 2020. Cost of sales for the full year 2021 was $22,064 compared with $11,468 for 2020 primarily due to the significantly higher volume of cannabis sold.
The Company recorded impairment charges totaling $57,096 in Q4 2021 compared with $83,979 in Q4 2020. For Flowr Canada, the Company recorded $24,552 of impairment against goodwill, $1,350 against intangible assets, and $14,498 against property, plant and equipment. For Holigen, an impairment charge of $4,661 was recorded against intangible assets and an impairment charge of $4,289 was recorded against property, plant and equipment.
Net loss attributable to shareholders of the Company totaled $61,277 for Q4 2021 compared with a loss of $100,454 for Q4 2020. Net loss attributable to shareholders of the Company for the full year 2021 was $85,532 compared with $125,621 for 2020. The change in net loss for was primarily due to higher revenue, lower SG&A expenses, lower impairment charges, reversal on share-based compensation, partially offset by higher depreciation and amortization, loss on disposal of subsidiary, higher other expenses, and lower income tax recovery.
During 2021, the Company significantly reduced its long-term debt outstanding under its senior amended and restated credit agreement ("ARCA") with a syndicate of lenders led by ATB Financial ("ATB Financial") by a total of $12,828, bringing the principal amount outstanding to $5,705 at the end of 2021 from $18,533 at December 31, 2020.
In Q1 2021, the Company closed a bought deal short form prospectus offering (the "Bought Deal") for gross proceeds of $15.9 million including the partial exercise of the over-allotment option ($14.4 million net proceeds after fees and transaction costs). In connection with the Offering, the Company issued 31,127,453 units (the "Unit") at a price of $0.51 per Unit (the "Issue Price"), with each Unit consisting of one common share in the capital of Flowr (each a "Common Share") and one full Common Share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant is exercisable to acquire one Common Share at an exercise price of $0.64 per Common Share for a period of two years from March 16, 2021 (the "Closing Date").
During Q3 2021, Flowr closed two private placement financings for total gross proceeds of $7,564,000 and issued 36,019,047 units ("Units") of the Company at a price of $0.21 per Unit, with each Unit consisting of one Common Share and one Common Share purchase warrant which entitles the warrant holder thereof to acquire one Common Share at an exercise price of $0.26 per share any time for a period of 42 months from the closing date.
Operational Updates
During 2021, Flowr achieved full operation in all 20 grow rooms at the K1 facility and improved the THC level by an average of +3.9% and consistently increased the output of flowers at high THC levels.
Flowr successfully introduced a new format of pre-rolls trademarked Dog Walkers which started delivery in Q4 2021. These 0.35g pre-rolls are packaged in an innovative tin pack of seven pre-rolls and have been listed in British Columbia, Alberta, and Ontario. The initial launch in British Columbia of the Dog Walkers sold out in less than two weeks.
During Q4 2021 the Company introduced its high-THC strain BC Strawnana with an average THC of 26.2%, which was accepted for listing in Ontario, British Columbia, Alberta, and Saskatchewan.
Over 50 new and exotic genetics have been trialed since Q2 2021. Three of these new strains have been approved for product listing in Q1 of 2022, significantly expanding the Company's product portfolio. These additional listings will continue Flowr's push to offer consumers differentiated exotic genetics, with high THC, high terpene contents, strong sensory profiles and premium quality buds.
In December 2021 the Company completed its first shipment of premium dried cannabis flowers from Canada to Israel, as part of the previously announced international supply agreement (the "Supply Agreement") with Focus Medical Herbs Ltd. ("Focus Medical"), a company which IM Cannabis Corp. (NASDAQ: IMCC) (CSE:IMCC) ("IMC") has an exclusive commercial agreement with in Israel. The first shipment consisted of premium cannabis across two strains for a total of $825,000. The shipment represents the Company's debut into the Israeli market and the first significant international export.
In December 2021, the Company successfully closed the previously announced sale of unused industrial land located in Kelowna, BC for gross sale price of $6.3 million in cash, including $5.3 million paid on closing and a further $1.0 million cash receivable within six months upon satisfaction of certain conditions. Pursuant to the credit agreement with a syndicate of senior lenders led by ATB Financial (the "Credit Facility"), the Company made an early principal repayment of $3 million towards the Credit Facility using proceeds from the land sale, reducing the principal amount outstanding to $5.7 million by the end of 2021. In exchange for the $3 million paydown, ATB Financial proceeded to release its security over Holigen Holdings Limited ("Holigen").
Holigen's indoor facility in Sintra, Portugal was fully operational with all grow rooms planted and producing E.U. GMP medical cannabis during Q4 2021. The BC Black Cherry and BC Strawnana strains from Flowr have been in production with the first harvest taking place in January 2022.
Key Events Subsequent to December 31, 2021
In February 2022 the Company entered into an agreement to sell its interest in the KRS R&D facility (the "KRS Facility") to Hawthorne Canada Limited ("Hawthorne") for an aggregate purchase price of $16 million (the "KRS Sale"), to be paid as follows: (i) an initial cash payment of $3.0 million; (ii) full extinguishment of the principal amount outstanding under the existing loan agreement between Flowr and Hawthorne for the construction of the KRS Facility on closing at approximately $12 million; and (iii) the balance of the purchase price of approximately $1.0 million paid in cash upon closing. The KRS Sale is expected to close in Q2 2022 and is subject to certain closing conditions.
Flowr has further increased its product offerings 2022 with the launch and success of BC Clementine Crush, BC Lemon Ice, BC Spiced Grape and BC Mango Melon OG, and a further seven new SKU's to be introduced in Q2 2022 across the provinces of Ontario, Quebec, British Columbia, Alberta and Saskatchewan. For the year 2022 to date, the BC Strawnana Dog Walker pre-rolls was the top ranked SKU and represented approximately 20% market share in Ontario in that size/price category (0.30 to 0.35 grams at above $10/gram), and continues to show strong traction in the provinces of British Colombia and Alberta.
The Company has shown significant growth in retail penetration across its core markets. In Ontario, over 65% of stores currently carry at least one Flowr product, representing significant growth from under 50% in August 2021. Across our other major markets, store distribution of Flowr products has grown from approximately 30% to over 60% and from approximately 27% to over 55% in British Colombia and Alberta, respectfully.
On April 19, 2022, the Company, through its wholly-owned subsidiary HHL, entered into a share purchase agreement (the "Purchase Agreement") with Akanda Corp. (NASDAQ: AKAN) ("Akanda") and Cannahealth Limited (the "Purchaser"), a wholly-owned subsidiary of Akanda. Pursuant to the Purchase Agreement, the Purchaser will acquire from HHL (the "Holigen Sale") all of interests in HL (including HL's wholly owned subsidiary RPK) for aggregate consideration of approximately $35 million.
Pursuant to the terms of the Purchase Agreement, the Company has agreed to sell HL to the Purchaser for total consideration payable of approximately $35 million (the "Purchase Price") consisting of: (i) $3,750,000 in cash; (ii) 1,900,000 common shares in the capital of Akanda (the "Consideration Shares") which closed at U.S.$10.30 per share on April 19, 2022; (iii) the indirect assumption by Akanda of RPK's indebtedness of approximately $5.1 million; and (iv) at least $0.8 million of interim funding to Holigen which has already been received by Flowr. If the Purchase Agreement does not close on or prior to May 31, 2022, the interim funding will be repaid to Akanda by the delivery of medical cannabis from Holigen at a price of EUR2.00 ($2.72) per gram or in cash, at the discretion of Flowr. In connection with the Transaction, Holigen will pay an advisory fee equal to 7% of the Purchase Price, 50% of which is payable in cash and 50% of which is payable in Consideration Shares.
In addition, Akanda agreed to subscribe for $1 million of common shares in the capital of Flowr (the "Private Placement") at a price per share of $0.07 per share. The Consideration Shares are subject to a customary six-month lockup.
The Holigen Sale closed on April 29, 2022 upon receiving the necessary approvals and satisfaction of other closing conditions.
As of December 31, 2021, the Company is in compliance with the senior debt to tangible net worth ratio and the minimum cash covenants. The Company was not in compliance with the minimum EBITDA covenant for the fourth quarter of 2021, the first time the covenant was tested. On May 20, 2022, the Company and its Senior Lenders led by ATB Financial entered into a second amendment to the ARCA (the "Second Amendment"), which included extension of the minimum EBITDA covenant and certain amendments to other financial covenants, repayment terms, and provided the Company with consent to complete its sale of the KRS Facility. Pursuant to the Second Amendment, the Company will proceed to make repayments in aggregate of $2,5 million. Upon closing of the sale of the KRS Facility, under the terms of the Second Amendment, the Company will make another $1.0 million repayment, bringing the principal balance owing down to $1.6 million.
The Company has recently listed for sale 17 acres of agricultural property located adjacent to the K1 Facility ("Flowr Forest"). As a non-core asset, the Company believes it will be able to sell Flowr Forest for proceeds of between $3 million to $4 million, which will be used to improve the financial position and working capital of the Company.
Effective immediately, John Chou has resigned from his position as Chief Financial Officer for medical reasons. Mike Willetts has been appointed Interim Chief Financial Officer of the Company effective immediately. Mr. Willetts is an experienced business executive with over 25 years of experience in financial leadership and is currently the Chief Financial Officer of GetSwift Technologies Limited and Forward Water Technologies Corp. The Company would like to wish Mr. Chou all the best with his future endeavours.
Adjusted EBITDA (Non-IFRS Measure)
Adjusted EBITDA is defined as net loss, plus (minus) income taxes (recovery), plus (minus) interest income (expense) including finance costs, plus depreciation and amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on biological assets and inventory sold, plus restructuring and transaction costs, plus (minus) loss (gain) on investments, plus impairment charges, and plus (minus) unusual or non-recurring items. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash used by operations.
For a full discussion of Flowr's operational and financial results for the year ended December 31, 2021, please refer to the Company's Management's Discussion & Analysis and Consolidated Financial Statements for the year ended December 31, 2021, which have been filed on SEDAR.
About The Flowr Corporation
The Flowr Corporation is a Canadian cannabis company with operations in Canada and the European Union. Its Canadian operating campus, located in Kelowna, British Columbia. Flowr aims to support improving outcomes through responsible cannabis use and, as an established expert in cannabis cultivation, strives to be the brand of choice for consumers and patients seeking the highest-quality craftsmanship and product consistency across a portfolio of differentiated cannabis products.
For more information, please visit flowrcorp.com or follow Flowr on Twitter: @FlowrCanada and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Tom Flow
Interim Chief Executive Officer
CONTACT INFORMATION:
INVESTORS & MEDIA:
investors@flowrcorp.com
All these people dishing on the AKANdyman, These are people who do not know how IPOs work! They ALWAYS HAVE DRASTIC DROPS IN PRICE! This is not the dot com bubble where a clown like Mark Cuban can be sitting at his desk making an minimal entry salary come up with broadcast.com IPO because he wanted easier access to listen to his beloved alma mater basketball games while at work and came up with the idea that was snatched up by Yahoo driving the price sky high instantly on the first day making Cuban a Billionaire and then watching Yahoo lose a fortune on the deal!
I should have gone over charts last night from my scanner and I probably would have gone in under $1 Obviously I could have gotten in at a better price even after I got them at $1.25 but with the volume so low and the % of gain at the moment, an obvious indicator that this stock is mega-low float, it could have gone to $2 in nothing flat! I was already fumbling w/ my calculator trying to get them at $1.18 and boom they were at $1.25
The biggest reason I got them where I did was that even while I was mostly committed to staying away from the OTC and sticking with the big boards, I decided to change my scanner from .80 to $10 because .01 to $10 was giving 1700 and more charts to go thru and why look under .80 if I feel I need to get the hell away from the OTC.
Damn I love these well established bottom plays. Excited about this one, try to find another like it on the big boards - it ain't out there, you know it as well as I do! I go over too many charts not to know!! So special here!
I was just about to message you the same; I was out getting street food and some wine got back home and saw it above $1.50; you were the first person I thought to write! I didn't know about the $1.60 range
I can't do that unless it is obviously stacked on L2 but more often than not it blows up in my face and I lose shares or I put myself under unnecessary stress from just a few more shares
The Kandy Man Cometh!!!
$AKAN $1.25 Was not quick enough with my calculator to get them @ $1.18 and did not go over charts from my scanner last night
But glad to get them Good to see you here Glens0
$AKAN $1.25 Was not quick enough with my calculator to get them @ $1.18 and did not go over charts from my scanner last night
But glad to get them Good to see you here Glens0
Probably a good thing to just follow them as far as today goes. Traded pretty choppy the Monday and Tuesday, not holding their gains well. Tuesday's volume should have been higher than Monday's, I get it that low volume take downs are no reason to sell but still that should not have happened that way, it should have followed thru with higher volume that Monday's for it to go where I was hoping for imo.
Yesterday's candlestick, if it had happened on Tuesday, without looking at the RSI information that you refer to would tell me that it could be oversold. It could go either way at this point imo. If they had a huge catalyst then that would be a game changer imo! Good luck
Good to know, thanks
If that is true that he wants to take this to the big boards, did he say this during the zoom conference? I did not watch; never been much into using zoom. There is only one way going to the big boards will happen and that is with an RS! And that never works out well for share holders!
Should make a nice move this week! Getting back to the message you sent asking if I look at RSI. I do not. At least not in the sense that you are talking about. I don't go to stockscores.com or anything like that. I use daily charts - chart formations and Japanese candlesticks and I can see the same strength in that! If RSI was saying overbought, yeah I was looking for it to come back down to $2 dollars myself but I could tell by the volume yesterday when AUVI was at $3.10 that is was go time!
I felt the same way last Friday and started getting out Friday and then Monday for a small profit!
Good morning Stark, What about them? Feb. 09, 2021 they went from $5 range to $35.78 on 118million shares, now AUVI is coming off of .90 cent range and had a lot more dilution added. The only thing in it's favor now is that the company has made strides in it's business developments.
If I were to look at DWAC's technicals before they went from $10 to $150 in a 2 day movement I would have gotten nothing out of them Could AUVI see $35 again? Maybe long term unless something major happens this week that sends it to the moon imo.
Those are my thoughts what are yours?
I'm hoping a 100+ million volume day today can send it to $10
We'll see
I got out with a profit today - sold yesterday @ $18.20 hoping to repurchase at $15.75 but did not stick to my guns and while talking on Skype to TDAmeritrade missed getting them below $17 and paide $17.70 to get back in
I should have known something was up pre-market today because yesterday was so bullish. And then the downgrade on the stock today, I did not realize until after market. I was trying to get out last 10 minutes of the day @ $15.20 just after they had been in the $15.40 range but I did not pull the trigger so I was out at $13.50 with a profit. Sucks ass but looking like the chart is out the window because of the catalyst driving the price down!
At the same time as this one was taking a dump, I was noticing AUVI looking bullish at $3.05 but that was nothing new to them for the past several days and I was hoping to get them closer to $2. Instead, I sold AERC after hours at $13.50 and put the proceeds into AUVI at $3.56 SHIT LUCK for me this week and AERC had so much hope going into the week! I think I made the right move. We'll see tomorrow!
Building a good base to launch from!
I want it to go where DWAC did; $150 in two days time!!!
I thought it was a bit silly people limiting today's action at $15
I just emailed the IR guy Ryan with this message:
Good morning Ryan,
My name is Cass, I am a technical analyst in the stock market. I went into AERC last Friday because of all the stocks either on the Nasdaq or NYSE, AERC currently has the most potential according to the charts! I believe AERC has the potential to make a move like DWAC did last year when DWAC went from $10 to $150 in 2 days! But all that depends on you and your ability to get a great press release out on Tuesday! Nothing happens on it's own!
Either way, best of luck, Cass
Not sure how possible that would be for a Monday PR but the chart looks so explosive that if that were to happen it could not happen at a better time!